Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €56.90 EUR
Change Today -0.96 / -1.66%
Volume 882.0
BRM On Other Exchanges
Symbol
Exchange
Sao Paulo
Frankfurt
As of 3:08 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

345 Park Avenue

New York, NY 10154

United States

Phone: 212-546-4000

Fax:

Bristol-Myers Squibb Company engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products worldwide. Products The company’s pharmaceutical products include chemically-synthesized drugs, or small molecules, and a portion of products produced from biological processes (involving recombinant DNA technology), called ‘biologics’. The company focuses on the following therapeutic classes: virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience; and cardiovascular. Baraclude Baraclude (entecavir) is a potent and selective inhibitor of hepatitis B virus that was approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus infection. Hepatitis C Franchise Daklinza (Daclatasvir (DCV)) is an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus infection (HCV) and was approved in combination with other medicinal products in the European Union across multiple genotypes in 2014. Sunvepra (Asunaprevir (ASV)) is an oral small molecule NS3 protease inhibitor for the treatment of HCV, and was approved as a dual regimen of DCV+ASV in Japan in 2014. Reyataz Franchise Reyataz (atazanavir sulfate) is a protease inhibitor for the treatment of HIV. The Reyataz Franchise includes Reyataz and combination therapy Evotaz (atazanavir 300 mg and cobicistat 150 mg), a once-daily single tablet two drug regimen combining Reyataz and Gilead Sciences, Inc.'s (Gilead) Tybost (cobicistat) for the treatment of HIV-1 infection in adults. Sustiva Franchise Sustiva (efavirenz) is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV. The Sustiva Franchise includes Sustiva, an antiretroviral drug used in the treatment of HIV, as well as bulk efavirenz which is included in the combination therapy Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), a once-daily single tablet three-drug regimen. Erbitux Erbitux (cetuximab) is an IgG1 monoclonal antibody designed to exclusively target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types, as well as some normal cells. Erbitux, a biological product, is approved in combination with irinotecan for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) who have failed an irinotecan-based regimen and as monotherapy for patients who are intolerant of irinotecan. Exclusive distribution rights in North America for cetuxmab were granted to the company by ImClone Systems Incorporated (ImClone). Erbitux has been approved by the FDA and other health authorities for monotherapy, for which there is no use patent. The use of Erbitux in combination with 5-Fluorouracil (an anti-neoplastic agent) is approved by the FDA. The company obtains its finished goods requirements for cetuximab for use in North America from Eli Lilly and Company (Lilly). Opdivo Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) on T and NKT cells. It is being investigated as an anticancer treatment. It is in Phase III trials in non-small cell lung cancer, renal cell cancer and melanoma. The company jointly owns a patent with Ono Pharmaceutical Co., LTD. covering Opdivo as a composition of matter that expires in 2027 in the U.S. (excluding potential patent term extension). In 2014, the FDA approved Opdivo for unresectable (inoperable) or metastatic melanoma, and disease progression following Yervoy. Opdivo was also approved in Japan in July 2014 for the same indication. The FDA has granted fast track designation for Opdivo in three tumor types: non-small cell lung cancer, renal cell carcinoma and metastatic melanoma. Sprycel Sprycel (dasatinib) is a multi-targeted tyrosine kinase inhibitor approved for the first-line treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase and the treatment of adults with chronic, accelerated, or myeloid o

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRM:GR €56.90 EUR -0.96

BRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $63.94 USD +0.08
Actavis plc $283.31 USD -2.44
Amgen Inc $158.95 USD -0.49
Medtronic PLC $74.32 USD -0.59
Novo Nordisk A/S kr366.60 DKK -4.00
View Industry Companies
 

Industry Analysis

BRM

Industry Average

Valuation BRM Industry Range
Price/Earnings 48.3x
Price/Sales 6.7x
Price/Book 7.0x
Price/Cash Flow 48.1x
TEV/Sales 5.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.